Insulet price target raised to $340 from $315 at Baird

Baird analyst Jeff Johnson raised the firm’s price target on Insulet to $340 from $315 and keeps an Outperform rating on the shares. The analyst met with management and said while he is comfortable in the company’s ability near term to maintain the market-leading AID position O5 has carved out recently in the U.S., he also left his meetings incrementally comfortable in the company’s ability to sustain that market leading position over coming years, even as other patch pump companies invariably come to market.